Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... , EXTON, Pa., Sept. 8 For ... been ranked as one of the fastest-growing, privately-held companies in the ... Wharton Small Business Development Center, the Entrepreneurs, Forum of Greater Philadelphia, ... Over the past five years, BioTrends has become an established ...
... YORK, Sept. 8 The Alzheimer,s Drug Discovery Foundation ... from the biotechnology industry and academia worldwide to apply for ... Dementia Biomarker Research Award . The goal of the ... aid in early diagnosis, detection and disease monitoring of Lewy ...
... NEW YORK, Sept. 8 Reportlinker.com announces that a ... , Nanoporous Materials , ... , This report analyzes the Global Market for ... for Nanoporous (Microporous) Materials by the following product segments: Zeolites, Activated ...
Cached Biology Technology:BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year 2Alzheimer's Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program 2Reportlinker Adds Nanoporous Materials Report 2Reportlinker Adds Nanoporous Materials Report 3Reportlinker Adds Nanoporous Materials Report 4Reportlinker Adds Nanoporous Materials Report 5Reportlinker Adds Nanoporous Materials Report 6
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... advances across the spectrum of science, technology, engineering ... through engaging table-top exhibits at the Coalition for ... Reception. The exhibition/reception will be held from 5:30 ... Rooms B338-340 of the Rayburn House Office Building ...
... old excuse, "I am only overweight because of my ... more evidence that the way our bodies digest and ... for every person. The budding discipline of metabolomics strives ... scientists and food chemists at the Technische Universitaet Muenchen ...
... As published today in Science , researchers from ... of plasticity in how transcription factors, the proteins that ... maintain their function over large evolutionary distances. The ... genes that they regulate by binding to short, sequence-specific ...
Cached Biology News:Science returns to Capitol Hill spotlight at April 14 exhibition 2Science returns to Capitol Hill spotlight at April 14 exhibition 3Science returns to Capitol Hill spotlight at April 14 exhibition 4Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 2Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 3Rewiring of gene regulation across 300 million years of evolution 2
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Goat anti-mouse gamma chain-HRP...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Phospho-C/EBPbeta (Thr235) Antibody...
Biology Products: